Free Trial
→ What Elon Musk's Cybercab Reveal Could Mean for Investors (From Brownstone Research) (Ad)tc pixel
NASDAQ:CODX

Co-Diagnostics Q3 2026 Earnings Date & Estimates

Co-Diagnostics logo
$0.36 -0.02 (-4.89%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$0.38 +0.02 (+4.87%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Co-Diagnostics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Co-Diagnostics in Q3 2026

Co-Diagnostics is expected to post earnings of -$1.25 per share on revenue of $169 thousand. In the same quarter a year earlier Co-Diagnostics reported -$4.80 per share on revenue of $145.38 thousand. Co-Diagnostics last reported on August 13, 2026, posting -$1.46 per share and beating the -$3.00 consensus estimate. Co-Diagnostics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.25
Expected Revenue
$169 thousand
Prior-Year EPS
-$4.80
Prior-Year Revenue
$145.38 thousand
Expected Revenue Growth
+16.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.46 (Beat by +$1.54)
Last Quarter Revenue
$166.13 thousand
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Co-Diagnostics Q3 2026 Earnings FAQ

Co-Diagnostics (NASDAQ:CODX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Co-Diagnostics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Co-Diagnostics to post earnings of -$1.25 per share for Q3 2026.

The consensus revenue estimate for Co-Diagnostics is $169 thousand for Q3 2026.

Co-Diagnostics Earnings Headlines

Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast
October 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-announces-third-quarter-2026-earnings-release-date-and-webcast-302923340.html
Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test
October 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-diagnostics-announces-publication-of-peer-reviewed-hpv-screening-study-using-cosaras-saragene-test-302923321.html
$250,000/Month- How You Can Learn from President Trump
President Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get access to the same fund for less than $20.tc pixel
November 5 at 1:00 AM  |  The Oxford Club (Ad)
Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
October 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-diagnostics-completes-clinical-study-and-regulatory-submission-for-point-of-care-tuberculosis-test-sets-stage-for-commercial-launch-in-india-302920079.html
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
October 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-diagnostics-invited-by-saudi-ministry-to-participate-in-strategic-manufacturing-forum-302913915.html
Co-Diagnostics Plans Special Meeting After Quorum Shortfalls
October 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CODX/pressreleases/8113327/co-diagnostics-plans-special-meeting-after-quorum-shortfalls/
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX) is a molecular diagnostics company that develops and commercializes diagnostic tests and laboratory technologies. Based in Salt Lake City, Utah, the company focuses on assays that detect genetic material from infectious diseases and other medical conditions.

The company’s core technology is its CoPrimer platform, which is designed to support the development of molecular tests using specialized primer technology. Products associated with the platform include the Logix Smart line of real-time polymerase chain reaction (PCR) assays, covering applications such as respiratory and other infectious diseases. Co-Diagnostics has also developed tests for conditions including tuberculosis and mosquito-borne diseases, with product availability and regulatory status varying by jurisdiction.

Founded in 2013, Co-Diagnostics serves clinical laboratories, healthcare providers, and distribution partners in the United States and international markets. Its tests and systems may be offered for research, laboratory, or diagnostic use depending on applicable regulatory approvals, and the company continues to expand its molecular testing portfolio through internal development and commercialization partnerships.

View Co-Diagnostics Profile
Earnings Tools